Figure 2.
Aggregated reported annualized bleeding rate data for hemophilia A and B clinical trials before (blue) and after (maroon) receiving the described recombinant AAV vectors. The dotted line denotes an annualized bleeding rate of 1.AAV8-wt-FIX, also known as scAAV2/8-LP1-hFIXco. Data from Nathwani et al.45 AMT-060 data from Miesbach et al.12 AMT-061, now etranocogene dezaparvovec, data from Pipe et al.8 SPK-9001, now fidancogene elaparvovec, data from George et al.9 BMN270, now valoctocogene roxaparvovec, data from Pasi et al.11 SPK-8011 data from George et al.14

Aggregated reported annualized bleeding rate data for hemophilia A and B clinical trials before (blue) and after (maroon) receiving the described recombinant AAV vectors. The dotted line denotes an annualized bleeding rate of 1.AAV8-wt-FIX, also known as scAAV2/8-LP1-hFIXco. Data from Nathwani et al.45  AMT-060 data from Miesbach et al.12  AMT-061, now etranocogene dezaparvovec, data from Pipe et al. SPK-9001, now fidancogene elaparvovec, data from George et al. BMN270, now valoctocogene roxaparvovec, data from Pasi et al.11  SPK-8011 data from George et al.14 

Close Modal

or Create an Account

Close Modal
Close Modal